SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCS
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (33)6/14/2001 11:24:02 PM
From: Spekulatius  Read Replies (1) of 78
 
The trouble with the Abarelix approval is quite a surprise for me. With AMGN directing the clinical trials, i felt that this would be a slam dunk. I have been out of this stock, because I liked the trading profits after the surge from the teens, not because of concerns with Abarelix. It certainly does not pay to bet against Avalon and Miljenko!
If Abarlix has safety problems for prostate cancer indication, endometriosis is dead as well. So, I feel that without Abarelix, PRCS may go down close to the 6$ cash value...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News